Bert Haenen

sr associate scientific director nonclinical safety

Beerse, Flemish Region, Belgium

About

Experience

  • The Janssen Pharmaceutical Companies of Johnson & Johnson (9 yrs 5 mos)
    • Senior Toxicologist
      Feb 2017 - Present · 9 yrs 5 mos

    • Toxicology Expert
      Feb 2017 - Present · 9 yrs 5 mos

  • senior consultant non-clinical development at 3D-PharmXchange
    Oct 2010 - Jan 2017 · 6 yrs 4 mos

    3D-PharmXchange is a consultancy firm providing integrated and immediate drug development and project management solutions to Biotech and Pharma companies. 3D-PharmXchange can take responsibility of interim management, complete development program design, organizational development, and consultancy projects. We make a difference by focusing on the creation of added value and accelerating time to value for our clients. 3D-PharmXchange offers you extensive strategic and operational experience in drug development and in project and line management.

  • safety assessment compound leader at Organon/Schering Plough/MSD
    Oct 2005 - Sep 2010 · 5 yrs

    Bert worked as a safety assement compound leader at Merck, Schering Plough and Organon for 5 years. In this role, he gained broad experience in the non-clinical development of compounds for various indications, including small molecules, biologics and vaccines. While in the industry and based experience, he participated in multiple scientific and developmental interactions with regulatory bodies.

  • project toxicologist at organon/Schering Plough
    2005 - 2010 · 5 yrs

  • sr non-clinical assessor human medicines at Dutch Medicines Evaluation Board
    May 1997 - Oct 2005 · 8 yrs 6 mos

    Prior to joining the pharmaceutical industry Bert was senior non-clinical assessor for the Medicines Evaluation Board in The Netherlands for 8 years. In this role, he was involved in the non-clinical assessment of European Registration Dossiers, Clinical Trial Applications and Scientific Advice procedures. He was also involved in issuing multiple non-clinical guidelines for the European Medicines Agency (EMA).